Loading
A phase 2 trial of tislelizumab, gemcitabine, cisplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by National Cheng-Kung University Hospital, not yet recruiting.
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma is a phase 2 interventional study registered as NCT06903273 by National Cheng-Kung University Hospital, with a registry enrolment figure of 35 participants, started 2025-07-01 and due to reach its primary completion in 2028-07-01. Interventions recorded: Tislelizumab. Conditions listed: Cholangiocarcinoma, Biliary Tract Cancer (BTC). Sites: Taiwan. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/